Researchers from the Cellular Biomedicine Group presented data on February 18 at the Stem Cell Summit in New York City supporting safety and efficacy of the company’s cell-based therapy for patients with knee osteoarthritis (OA).
Wei “William” Cao, PhD, BM, CEO of the Palo Alto, CA-based company, reported that three-month data from a phase I/IIa clinical trial of intra-articular injections of autologous human adipose-derived mesenchymal precursor cells in patients with knee OA show no adverse events and statistically significant improvement in knee pain, knee mobility, and prolonged walking distance.
Investigators observed increased cartilage thickness and reduction of bone marrow lesions in some patients. Full analysis of six-month follow-up data and additional studies to confirm the cartilage regrowth are ongoing.
